← Browse by Condition
Medical Condition

b cell lymphoma

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 1, Phase 2

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — b cell lymphoma Clinical Trials

How many clinical trials are currently recruiting for b cell lymphoma?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for b cell lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for b cell lymphoma?
b cell lymphoma research spans Phase 1 (4 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a b cell lymphoma clinical trial?
Eligibility criteria for b cell lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
4
Phase 2
1
Top Sponsors
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd 1 trial
Iksuda Therapeutics Ltd. 1 trial
Hospices Civils de Lyon 1 trial
Chinese PLA General Hospital 1 trial
M.D. Anderson Cancer Center 1 trial

Recruiting Clinical Trials

NCT07093073 Phase 1
Recruiting
Clinical Study of U01(ssCART-19) in Patients With B-Cell Lymphoma
Enrollment
30 pts
Location
China
Sponsor
Shanghai Unicar-Therapy Bio-me...
View Trial →
NCT05365659 Phase 1
Recruiting
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Enrollment
140 pts
Location
United States, Austr...
Sponsor
Iksuda Therapeutics Ltd.
View Trial →
NCT03787056
Recruiting
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Enrollment
410 pts
Location
France
Sponsor
Hospices Civils de Lyon
View Trial →
NCT07775508 Phase 1
Recruiting
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma
Enrollment
18 pts
Location
China
Sponsor
Chinese PLA General Hospital
View Trial →
NCT05615636 Phase 2
Recruiting
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Enrollment
36 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT07369492 Phase 1
Recruiting
Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma
Enrollment
30 pts
Location
China
Sponsor
Jiangsu Topcel-KH Pharmaceutic...
View Trial →

Related Conditions

b cell non hodgkin lymphoma (1) diffuse large b cell lymphoma (1) follicular lymphoma (1) mantle cell lymphoma (1) cancer (1) breast cancer (1) gastric cancer (1) renal cancer (1) prostate cancer (1) melanoma (1) lung cancer (1) hepatocellular cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology